Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	16.5	18.82	24.71	20.39	7.82	0.4
Research & Development	93.2	86.14	82.27	51.1	13.7	3.92
Operating Expenses	109.7	104.96	106.99	71.49	21.53	4.32
Operating Income	-109.7	-104.96	-106.99	-71.49	-21.53	-4.32
Interest Expense / Income	0	0	0	0	0.65	0
Other Expense / Income	-10.36	-8.31	-2.2	-0.4	-0.06	-0.01
Pretax Income	-99.34	-96.66	-104.79	-71.1	-22.12	-4.32
Net Income	-99.34	-96.66	-104.79	-71.1	-22.12	-4.32
Preferred Dividends	0	0	0	0	1.87	0
Net Income Common	-99.34	-96.66	-104.79	-71.1	-23.99	-4.32
Shares Outstanding (Basic)	56	45	40	40	7	3
Shares Outstanding (Diluted)	56	45	40	40	7	3
Shares Change	37.72%	13.13%	1.19%	462.91%	170.75%	2.80%
EPS (Basic)	-2.01	-2.14	-2.62	-1.80	-3.42	-1.66
EPS (Diluted)	-2.01	-2.14	-2.62	-1.80	-3.42	-1.66
Free Cash Flow	-86.97	-83.71	-82.43	-52.27	-19.92	-3.08
Free Cash Flow Per Share	-1.56	-1.85	-2.06	-1.32	-2.84	-1.19
EBITDA	-97.72	-94.98	-103.13	-69.71	-21.46	-4.31
Depreciation & Amortization	1.62	1.67	1.66	1.39	0.01	0.01
EBIT	-99.34	-96.66	-104.79	-71.1	-21.47	-4.32

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).